William P. Sheridan's most recent trade in Biocryst Pharmaceuticals Inc. was a trade of 159,739 Common Stock done at an average price of $16.9 . Disclosure was reported to the exchange on March 10, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.87 per share. | 10 Mar 2022 | 159,739 | 39,354 (0%) | 0% | 16.9 | 2,694,797 | Common Stock |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.22 per share. | 10 Mar 2022 | 148,302 | 199,093 (0%) | 0% | 3.2 | 477,532 | Common Stock |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 148,302 | 0 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 17.64 per share. | 10 Mar 2022 | 1,400 | 37,954 (0%) | 0% | 17.6 | 24,696 | Common Stock |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 164,000 | 164,000 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 35,000 | 50,791 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.02 per share. | 27 May 2021 | 91,814 | 14,475 (0%) | 0% | 15.0 | 1,379,046 | Common Stock |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 27 May 2021 | 71,759 | 14,475 (0%) | 0% | 15 | 1,076,385 | Common Stock |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.59 per share. | 27 May 2021 | 64,299 | 100,388 (0%) | 0% | 5.6 | 359,431 | Common Stock |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2021 | 64,299 | 0 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2021 | 35,701 | 64,299 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.59 per share. | 27 May 2021 | 35,701 | 75,135 (0%) | 0% | 5.6 | 199,569 | Common Stock |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2021 | 24,959 | 21,614 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.73 per share. | 27 May 2021 | 24,959 | 39,434 (0%) | 0% | 4.7 | 118,056 | Common Stock |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2021 | 21,614 | 0 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.73 per share. | 27 May 2021 | 21,614 | 36,089 (0%) | 0% | 4.7 | 102,234 | Common Stock |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2021 | 11,099 | 5,901 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.45 per share. | 27 May 2021 | 11,099 | 86,234 (0%) | 0% | 5.5 | 60,490 | Common Stock |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.45 per share. | 27 May 2021 | 5,901 | 106,289 (0%) | 0% | 5.4 | 32,160 | Common Stock |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2021 | 5,901 | 0 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Senior VP - CMO | Sale of securities on an exchange or to another person at price $ 11.57 per share. | 22 Feb 2021 | 41,250 | 11,475 (0%) | 0% | 11.6 | 477,263 | Common Stock |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Senior VP - CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2021 | 41,250 | 0 | - | - | Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Senior VP - CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.15 per share. | 22 Feb 2021 | 41,250 | 52,725 (0%) | 0% | 4.2 | 171,188 | Common Stock |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Senior VP - CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2020 | 335,000 | 335,000 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | William P. Sheridan | Senior VP - CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2020 | 17,000 | 17,000 | - | - | Emp. Stock Option (Right to Buy) |